BC Innovations | Dec 6, 2019
Targets & Mechanisms

A view of immune reprogramming from ASH

ASH presentations on immune reprogramming point to new targets and mechanisms that control macrophage and T cell phenotype switching, and highlight the phenomenon's translational relevance in diseases beyond solid tumors. Strategies to convert immunosuppressive macrophage...
BC Innovations | Sep 19, 2018
Distillery Techniques

Drug platforms

TECHNOLOGY: Cell therapy A method for differentiating HSPCs into megakaryocytes by overexpressing or activating one of 15 genes could help generate platelet-producing megakaryocyte colonies for thrombocytopenia. The method involves two steps: generating megakaryocyte progenitor cells...
BioCentury | Oct 24, 2016
Emerging Company Profile

RORing against resistance

  Oncternal Therapeutics Inc.’s ROR1 inhibitor could be combined with BTK inhibitors to increase response rates in chemotherapy-resistant or refractory hematologic cancers such as chronic lymphocytic leukemia and mantle cell lymphoma. The Bruton’s tyrosine kinase...
BC Week In Review | Sep 5, 2016
Clinical News

TK216: Phase I started

Oncternal dosed the first patient an open-label, dose-escalation, dose-expansion, U.S. Phase I trial to evaluate IV TK216 in about 45 patients ages >=12. Oncternal gained the compound from its June merger with Tokalas Inc. (see...
BC Week In Review | Jun 6, 2016
Company News

Oncternal, Tokalas deal

Cancer companies Oncternal and Tokalas merged and will retain the Oncternal name. Oncternal’s cirmtuzumab (UC-961), a humanized IgG1 mAb against receptor tyrosine kinase-like orphan receptor 1 (ROR1), is in Phase I testing to treat relapsed...
BC Innovations | Jul 24, 2014
Distillery Techniques

Technology: Disease models

Approach Summary Licensing status Publication and contact information Disease models Mouse model of Ewing's sarcoma with cell-specific expression of a transgenic Ewing sarcoma breakpoint region 1 (EWSR1; EWS)-Friend leukemia virus integration 1 (FLI1) fusion protein...
BioCentury | Jan 27, 2014
Emerging Company Profile

Salarius: Kicking LSD

Salarius Pharmaceuticals LLC is using a fragment-based discovery approach to develop safer inhibitors of lysine-specific histone demethylase, an epigenetic target that is up-regulated in hormone-dependent cancers and essential in specific forms of acute myelogenous leukemia...
BC Innovations | Nov 29, 2012
Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms Inducing vascular endothelial cells from amniotic stem cells Cell culture and mouse studies identified methods to reprogram amniotic cells into vascular endothelial cells. In human...
BC Innovations | Apr 26, 2012
Cover Story

Cancer cell line encyclopedias

Two research teams have independently developed large-scale screening platforms to profile hundreds of human cancer cell lines and identify drug sensitivity biomarkers. 1,2 Novartis AG , a member of one of the groups, is now using...
BC Innovations | Apr 26, 2012
Distillery Techniques

Technology: Assays & screens

This week in techniques Approach Summary Licensing status Publication and contact information Assays & screens Comprehensive cell-line panel for predicting responses to cancer therapies A collection of hundreds of cancer cell lines could help predict...
Items per page:
1 - 10 of 10